scholarly journals Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients

2012 ◽  
Vol 108 (1) ◽  
pp. 139-148 ◽  
Author(s):  
J M Willder ◽  
S J Heng ◽  
P McCall ◽  
C E Adams ◽  
C Tannahill ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Biochemical Relapse ◽  
Receptor Phosphorylation

scholarly journals Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients

Oncotarget ◽  
2016 ◽  
Vol 8 (3) ◽  
pp. 4875-4887 ◽  
Author(s):  
SC Patek ◽  
JM Willder ◽  
JS Heng ◽  
B Taylor ◽  
PG Horgan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Receptor Phosphorylation ◽  
Poor Outcome

Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy

2017 ◽  
Vol 194 (4) ◽  
pp. 325-332 ◽  
Author(s):  
Gunnar Lohm ◽  
Konrad Neumann ◽  
Volker Budach ◽  
Thomas Wiegel ◽  
Stefan Hoecht ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Salvage Radiotherapy ◽  
Biochemical Relapse

scholarly journals PO-0738: PET with 18F-Choline for evaluation of prostate cancer patients with biochemical relapse/persistence

2017 ◽  
Vol 123 ◽  
pp. S388-S389
Author(s):  
H. Pérez Montero ◽  
M.A. Cabeza ◽  
A. Gómez ◽  
S.G. Guardado ◽  
J.F. Pérez-Regadera
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Biochemical Relapse

YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients

2020 ◽  
Vol 21 (13) ◽  
pp. 919-928
Author(s):  
Ana Afonso ◽  
Jani Silva ◽  
Ana Rita Lopes ◽  
Sara Coelho ◽  
Ana Sofia Patrão ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Cox Regression ◽  
Progression Free Survival ◽  
Castration Resistant Prostate Cancer ◽  
Allelic Discrimination ◽  
Cox Regression Analysis ◽  
Castration Resistant ◽  
Increased Risk

Aim: To evaluate the influence of YB-1 rs10493112 variant as a genetic marker for response to second-generation androgen receptor axis-target agents. Methods: A hospital-based cohort study of 78 patients with metastatic castration-resistant prostate cancer was conducted. Genotyping was performed by TaqMan® allelic discrimination technology. Main results: In abiraterone-treated and high-risk patients, YB-1 rs10493112 AA genotype carriers showed lower progression-free survival than C allele genotype patients (4 vs 17 months; p = 0.009). For carriers of AA genotype, multivariate Cox regression analysis revealed a fivefold increased risk of progression (p = 0.035). Conclusion: The study findings suggest that, for metastatic and castration-resistant prostate cancer patients, this polymorphism might be a putative marker for the clinical outcome.

Sign in / Sign up

Export Citation Format

Share Document